Literature DB >> 8957237

Effect of cilostazol, a cAMP phosphodiesterase inhibitor, on nitric oxide production by vascular smooth muscle cells.

U Ikeda1, M Ikeda, S Kano, T Kanbe, K Shimada.   

Abstract

We investigated the effects of cilostazol, a cAMP phosphodiesterase inhibitor, on nitric oxide (NO) synthesis in cultured rat vascular smooth muscle cells. Incubation of the cultures with interleukin-1 beta (10 ng/ml) for 24 h caused a significant increase in the accumulation of nitrite, a stable metabolite of NO. Although cilostazol itself showed no effect on nitrite accumulation, it stimulated interleukin-1 beta-induced nitrite accumulation in a concentration-dependent manner (10(-8)-10(-5) M). This effect of cilostazol was completely abolished in the presence of NG-monomethyl-L-arginine, actinomycin D or dexamethasone. The cilostazol-induced nitrite production was accompanied by increased inducible NO synthase protein expression. In the presence of dibutyryl-cAMP, interleukin-1 beta-induced nitrite accumulation was further increased, but the stimulatory effect of cilostazol on nitrite accumulation was blunted. The effect of cilostazol was also abolished in the presence of Rp-8-bromoadenosine-3',5-cyclic monophosphorothioate, a competitive inhibitor of protein kinase A. Addition of cilostazol to the cultures significantly increased intracellular cAMP levels of vascular smooth muscle cells. These results indicate that cilostazol increases NO synthesis in interleukin-1 beta-stimulated smooth muscle cells, at least partially through a cAMP-dependent pathway.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8957237     DOI: 10.1016/s0014-2999(96)00551-1

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  9 in total

1.  Endothelial dysfunction in the smokers can be improved with oral cilostazol treatment.

Authors:  Kyu Seop Kim; Hyung Seo Park; Il Soon Jung; Jae-Hyeong Park; Kye Taek Ahn; Seon-Ah Jin; Yong Kyu Park; Jun Hyung Kim; Jae-Hwan Lee; Si Wan Choi; Jin-Ok Jeong; In-Whan Seong
Journal:  J Cardiovasc Ultrasound       Date:  2011-03-31

Review 2.  Cilostazol for Secondary Stroke Prevention: History, Evidence, Limitations, and Possibilities.

Authors:  Adam de Havenon; Kevin N Sheth; Tracy E Madsen; Karen C Johnston; Tanya N Turan; Kazunori Toyoda; Jordan J Elm; Joanna M Wardlaw; S Claiborne Johnston; Olajide A Williams; Ashkan Shoamanesh; Maarten G Lansberg
Journal:  Stroke       Date:  2021-09-14       Impact factor: 10.170

Review 3.  Drug treatment of intermittent claudication.

Authors:  Douglas Jacoby; Emile R Mohler
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 4.  Exercise training and peripheral arterial disease.

Authors:  Tara L Haas; Pamela G Lloyd; Hsiao-Tung Yang; Ronald L Terjung
Journal:  Compr Physiol       Date:  2012-10       Impact factor: 9.090

5.  Cilostazol suppresses neointimal hyperplasia in canine vein grafts.

Authors:  Fabio A Kudo; Yuka Kondo; Akihito Muto; Keiko Miyazaki; Alan Dardik; Masayasu Nishibe; Toshiya Nishibe
Journal:  Surg Today       Date:  2009-02-07       Impact factor: 2.549

6.  An experimental study of the effect of pre-operative administration of cilostazol on random skin flap survival in rats: double blinded randomized controlled trial.

Authors:  Chairat Burusapat; Janjira Paengnoi; Kantang Satayasoontorn
Journal:  Ann Surg Innov Res       Date:  2015-04-29

7.  Model difference in the effect of cilostazol on the development of experimental pulmonary hypertension in rats.

Authors:  Toshikazu Ito; Erquan Zhang; Ayaka Omori; Jane Kabwe; Masako Kawai; Junko Maruyama; Amphone Okada; Ayumu Yokochi; Hirofumi Sawada; Yoshihide Mitani; Kazuo Maruyama
Journal:  BMC Pulm Med       Date:  2021-11-20       Impact factor: 3.317

8.  Cilostazol improves endothelial function in acute cerebral ischemia patients: a double-blind placebo controlled trial with flow-mediated dilation technique.

Authors:  Seong-Joon Lee; Jin Soo Lee; Mun Hee Choi; Sung Eun Lee; Dong Hoon Shin; Ji Man Hong
Journal:  BMC Neurol       Date:  2017-08-29       Impact factor: 2.474

9.  Cilostazol restores autophagy flux in bafilomycin A1-treated, cultured cortical astrocytes through lysosomal reacidification: roles of PKA, zinc and metallothionein 3.

Authors:  Ha Na Kim; Bo-Ra Seo; Hyunjin Kim; Jae-Young Koh
Journal:  Sci Rep       Date:  2020-06-08       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.